Overview Dividends

(OSUR) OraSure Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US68554V1089

Rapid Tests, Collection Devices, Genomic Kits, Microbiome Kits

OSUR EPS (Earnings per Share)

EPS Growth (3Y CAGR): -46.53%
EPS Trend (3Y Correlation): -87.8%

OSUR Revenue

Revenue Growth (3Y CAGR): -78.71%
Revenue Trend (3Y Correlation): -81.7%

Risk via 10d forecast
Volatility	50.7%
Value at Risk 5%th	77.9%

Reward
Sharpe Ratio	-0.82
Alpha Jensen	-54.90

Character
Hurst Exponent	0.558
Beta	0.735

Drawdowns 3y
Max DD	72.10%
Mean DD	35.89%

Description: OSUR OraSure Technologies October 28, 2025

OraSure Technologies, Inc. (NASDAQ: OSUR) is a U.S.–based developer and manufacturer of point-of-care diagnostic and specimen-collection devices, serving markets in the United States, Europe, Africa and beyond. Incorporated in 2000 and headquartered in Bethlehem, Pennsylvania, the firm operates within the Health Care Supplies sub-industry.

The company’s portfolio spans rapid antigen and antibody tests-including the OraQuick HIV and HCV self-tests, a syphilis health-check, an Ebola rapid antigen test, and several InteliSwab COVID-19 formats-as well as oral-fluid collection devices, drug-testing systems, and the Q.E.D. saliva alcohol test. It also markets genomic collection kits (Oragene, ORAcollect), urine-collection devices (Colli-Pee), and microbiome sampling products (OMNIgene GUT/SALIVA). A pipeline molecular self-test for chlamydia and gonorrhea is slated for regulatory filing in 2025.

According to the most recent Form 10-K, OSUR reported FY 2023 revenue of approximately $221 million, a year-over-year increase of about 10 % driven largely by sustained demand for home-based infectious-disease testing post-COVID-19. Operating margin improved to roughly 12 % as the firm leveraged higher-margin consumables and achieved cost efficiencies in its supply chain. The company holds around $70 million in cash and short-term investments, providing runway for R&D and potential acquisitions. Key sector drivers include the expanding U.S. point-of-care diagnostics market (projected CAGR ≈ 6 % through 2030) and growing consumer preference for at-home health testing, while regulatory clearance timelines and competitive pressure from larger players (e.g., Abbott, Roche) remain material uncertainties.

For a deeper quantitative assessment, you may find ValueRay’s platform useful for modeling OSUR’s valuation.

OSUR Stock Overview

Market Cap in USD	172m
Sub-Industry	Health Care Supplies
IPO / Inception	1986-11-12
Return 12m vs S&P 500	-49.8%
Analyst Rating	3.50 of 5

OSUR Dividends

Currently no dividends paid

OSUR Growth Ratios

CAGR	-22.71%
CAGR/Max DD Calmar Ratio	-0.31
CAGR/Mean DD Pain Ratio	-0.63
Current Volume	522.3k
Average Volume	511.5k

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-60.2m TTM) > 0 and > 6% of Revenue (6% = 6.02m TTM)

FCFTA -0.03 (>2.0%) and ΔFCFTA -17.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 241.9% (prev 143.7%; Δ 98.13pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.09 (>3.0%) and CFO -39.9m > Net Income -60.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 7.03 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (73.0m) change vs 12m ago -2.12% (target <= -2.0% for YES)

Gross Margin 50.61% (prev 45.01%; Δ 5.60pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 22.63% (prev 48.32%; Δ -25.70pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -5.03 (EBITDA TTM -56.0m / Interest Expense TTM 9.54m) >= 6 (WARN >= 3)

Altman Z'' -1.11

(A) 0.57 = (Total Current Assets 283.0m - Total Current Liabilities 40.2m) / Total Assets 423.1m

(B) -0.36 = Retained Earnings (Balance) -152.9m / Total Assets 423.1m

(D) -2.83 = Book Value of Equity -173.0m / Total Liabilities 61.1m

Total Rating: -1.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 21.46

1. Piotroski 2.0pt = -3.0

2. FCF Yield 43.97% = 5.0

3. FCF Margin -13.67% = -5.13

4. Debt/Equity 0.04 = 2.50

5. Debt/Ebitda 3.62 = -2.39

6. ROIC - WACC (= -21.70)% = -12.50

7. RoE -15.55% = -2.50

8. Rev. Trend -81.71% = -6.13

9. EPS Trend -87.78% = -4.39

What is the price of OSUR shares?

As of November 12, 2025, the stock is trading at USD 2.46 with a total of 522,310 shares traded.
Over the past week, the price has changed by -4.28%, over one month by -18.27%, over three months by -11.83% and over the past year by -41.98%.

Is OraSure Technologies a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, OraSure Technologies (NASDAQ:OSUR) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 21.46 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OSUR is around 1.75 USD . This means that OSUR is currently overvalued and has a potential downside of -28.86%.

Is OSUR a buy, sell or hold?

OraSure Technologies has received a consensus analysts rating of 3.50. Therefor, it is recommend to hold OSUR.

Strong Buy: 1
Buy: 0
Hold: 3
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the OSUR price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	4.8	93.1%
Analysts Target Price	4.8	93.1%
ValueRay Target Price	2	-19.9%

OSUR Fundamental Data Overview November 10, 2025

Market Cap USD = 171.8m (171.8m USD * 1.0 USD.USD)
P/S = 1.3667
P/B = 0.6013
P/EG = 2.3
Beta = 0.735
Revenue TTM = 100.4m USD
EBIT TTM = -48.0m USD
EBITDA TTM = -56.0m USD
Long Term Debt = 14.6m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 2.11m USD (from shortTermDebt, last quarter)
Debt = 13.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -203.0m USD (from netDebt column, last quarter)
Enterprise Value = -31.2m USD (171.8m + Debt 13.5m - CCE 216.5m)
Interest Coverage Ratio = -5.03 (Ebit TTM -48.0m / Interest Expense TTM 9.54m)
FCF Yield = 43.97% (FCF TTM -13.7m / Enterprise Value -31.2m)
FCF Margin = -13.67% (FCF TTM -13.7m / Revenue TTM 100.4m)
Net Margin = -60.02% (Net Income TTM -60.2m / Revenue TTM 100.4m)
Gross Margin = 50.61% ((Revenue TTM 100.4m - Cost of Revenue TTM 49.6m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 42.12%)
Tobins Q-Ratio = -0.07 (set to none) (Enterprise Value -31.2m / Total Assets 423.1m)
Interest Expense / Debt = 19.85% (Interest Expense 2.67m / Debt 13.5m)
Taxrate = -0.35% (negative due to tax credits) (47.0k / -13.3m)
NOPAT = -48.1m (EBIT -48.0m * (1 - -0.35%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 7.03 (Total Current Assets 283.0m / Total Current Liabilities 40.2m)
Debt / Equity = 0.04 (Debt 13.5m / totalStockholderEquity, last quarter 362.0m)
Debt / EBITDA = 3.62 (negative EBITDA) (Net Debt -203.0m / EBITDA -56.0m)
Debt / FCF = 14.79 (negative FCF - burning cash) (Net Debt -203.0m / FCF TTM -13.7m)
Total Stockholder Equity = 387.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.24% (Net Income -60.2m / Total Assets 423.1m)
RoE = -15.55% (Net Income TTM -60.2m / Total Stockholder Equity 387.3m)
RoCE = -11.94% (EBIT -48.0m / Capital Employed (Equity 387.3m + L.T.Debt 14.6m))
RoIC = -12.16% (negative operating profit) (NOPAT -48.1m / Invested Capital 395.8m)
WACC = 9.53% (E(171.8m)/V(185.3m) * Re(8.72%) + D(13.5m)/V(185.3m) * Rd(19.85%) * (1-Tc(-0.00)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.35%
Fair Price DCF = unknown (Cash Flow -13.7m)
EPS Correlation: -87.78 | EPS CAGR: -46.53% | SUE: 0.69 | # QB: 0
Revenue Correlation: -81.71 | Revenue CAGR: -78.71% | SUE: -4.0 | # QB: 0

Additional Sources for OSUR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle